Document Detail

Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients.
MedLine Citation:
PMID:  12060967     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the feasibility, efficacy, safety and side effects of routinely performed continuous venovenous hemofiltration (CVVH) with regional citrate anticoagulation using a citrate-containing substitution solution as compared with conventional systemic low-dose unfractionated heparin-anticoagulation in postoperative cardiac surgery patients. DESIGN/SETTING: Database review of all patients on CVVH during a three-year period at a cardiovascular intensive care unit of a tertiary referring university hospital. PATIENTS: Patients who had undergone cardiac surgery with acute or chronic renal failure were studied. Thirty-seven citrate CVVH courses in 31 patients (January to November 2000) and 59 heparin CVVH courses in 50 patients (1998 and 1999) had been undertaken postoperatively. Indications for hemofiltration were acute renal failure in 24 and chronic renal failure in 7 of the citrate patients, and acute renal failure in 44 and chronic renal failure in 6 of the heparin patients. INTERVENTIONS: CVVH with either regional citrate anticoagulation using a custom-made citrate-based substitution solution or unfractionated heparin anticoagulation. MEASUREMENTS: The following parameters were measured: median filtration time, hemofilters used per day, differences in creatinine and blood urea levels as opposed to baseline, blood loss within the first 24 h of hemofiltration, incidence of bleeding-related resternotomies, acidosis, and alkalosis. RESULTS: No significant differences in any of the measured parameters were registered. No serious electrolyte imbalance was observed in either group. Furthermore, the two groups did not differ in terms of mortality, duration of stay in the intensive care unit or in hospital, and restoration rate of normal renal function. CONCLUSIONS: We conclude that citrate-based regional anticoagulation is effective, safe and easy to use in CVVH following cardiac surgery and might become the first choice for anticoagulation in patients in whom the application of systemic heparin is contraindicated.
Michèle Thoenen; Edith R Schmid; Ulrich Binswanger; Rolf Schuepbach; Daniel Aerne; Daniel Schmidlin
Related Documents :
15764777 - A feasibility study of continuing dose-reduced warfarin for invasive procedures in pati...
12691397 - The use of recombinant activated factor vii to reverse warfarin-induced anticoagulation...
18005777 - Postoperative pulmonary embolism: timing, diagnosis, treatment, and outcomes.
19738137 - Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized c...
19681317 - Outcome of four-corner arthrodesis for advanced carpal collapse: circular plate versus ...
8225427 - Postoperative pulmonary complications and serial pulmonary functions and arterial blood...
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article    
Journal Detail:
Title:  Wiener klinische Wochenschrift     Volume:  114     ISSN:  0043-5325     ISO Abbreviation:  Wien. Klin. Wochenschr.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-06-13     Completed Date:  2002-10-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  21620870R     Medline TA:  Wien Klin Wochenschr     Country:  Austria    
Other Details:
Languages:  eng     Pagination:  108-14     Citation Subset:  IM    
Division of Cardiovascular Anaesthesia, Institute of Anaesthesiology, University Hospital, Zurich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / adverse effects,  therapeutic use*
Citric Acid / adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Feasibility Studies
Heart Diseases / surgery*
Heparin / adverse effects,  therapeutic use
Kidney Failure / therapy*
Middle Aged
Postoperative Complications / therapy*
Retrospective Studies
Reg. No./Substance:
0/Anticoagulants; 77-92-9/Citric Acid; 9005-49-6/Heparin
Comment In:
Wien Klin Wochenschr. 2002 Feb 15;114(3):78-80   [PMID:  12060972 ]
Erratum In:
Wien Klin Wochenschr 2002 Feb 28;114(4):164

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human monocyte stimulation by experimental whole body hyperthermia.
Next Document:  Hypertrophic osteoarthropathy caused by PGE1 in a patient with congestive heart failure during cardi...